Method for transporting a compound across the blood-brain barrier
The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier. The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier.
1. An isolated carrier, wherein the brain penetration or transcytosis across the blood-brain barrier of said carrier is greater than that of aprotinin:
(a) comprising AngioPep-1 (SEQ ID NO:4) or
(b) consisting of a polypeptide having the amino acid sequence RGKRNNFKTEEY(residues 8-19 of SEQ ID NO:4).
2. The carrier of claim 1 , consisting of a polypeptide having the amino acid sequence RGKRNNFKTEEY (residues 8-19 of SEQ ID NO:4).
3. The carrier of claim 1 , comprising AngioPep-1.
4. The carrier of claim 3 , consisting of AngioPep-1.
5. A conjugate comprising:
(a) a carrier comprising AngioPep-1 (SEQ ID NO:4) or consisting of a polypeptide having the amino acid sequence RGKRNNFKTEEY (residues 8-19 or SEQ ID NO:4), wherein the brain penetration or transcytosis across the blood-brain barrier of said carrier is greater than that of aprotinin, and
(b) an agent attached to said carrier, wherein said conjugate is able to cross the blood brain barrier.
6. The conjugate of claim 5 , wherein the carrier consists of a polypeptide having the amino acid sequence RGKRNNFKTEEY (residues 8-19 of SEQ ID NO:4).
7. The conjugate of claim 5 , wherein the carrier comprises AngioPep-1.
8. The conjugate of claim 5 , wherein the carrier consists of AngioPep-1.
9. The conjugate of any of claims 5 - 8 , wherein said agent has a maximum molecular weight of 160,000 Daltons.
10. The conjugate of claim 5 , wherein said agent is selected from the group consisting of a drug, a medicine, a protein, a peptide, an enzyme, an antibiotic, an anti-cancer agent, a a radioimaging agent, an antibody, a cellular toxin, a detectable label, and an anti-angiogenic compound.
11. The conjugate of claim 10 , wherein said drug is a small molecule drug having a molecular weight less than 1000 g/mol.
12. The conjugate of claim 10 , wherein said agent is an anticancer agent.
13. The conjugate of claim 12 , wherein said anticancer agent is paclitaxel.
14. The conjugate of claim 10 , wherein said agent is an antibody.
15. The conjugate of claim 5 , wherein transport of said conjugate across the blood-brain barrier does not affect blood-brain barrier integrity.
16. A pharmaceutical composition comprising a conjugate of claim 5 and a pharmaceutically acceptable excipient.
17. The pharmaceutical composition of claim 16 , wherein said composition can be administered intra-arterially, intra-nasally, intra-peritoneally, intravenously, intramuscularly, sub-cutaneously, transdermally, or per os.
18. A method of transporting an agent across the blood-brain barrier, comprising the administration of the conjugate of claim 5 .
19. A method of transporting an agent across a blood-brain barrier, which comprises the step of administering to an individual the pharmaceutical composition of claim 16 .
20. The conjugate of claim 5 , wherein said agent is a therapeutic agent.